RNS: RELEASE | 31 August 2023

ImmuPharma PLC
("ImmuPharma" or the "Company")

INTERIM RESULTS
for the six months ended 30 June 2023

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2023 (the "Period").

Key Highlights (including post Period review)

Financials

- Loss for the Period of £0.8m (30 June 2022: £1.7m)
- Research and development expenses of £0.8m (30 June 2022: £1.0m)
- Administrative expenses of £0.4m (30 June 2022: £0.6m)
- Share based expense of £0.1m (30 June 2022: £0.1m)
- Cash balance of £0.2m as at 30 June 2023 (31 December 2022: £0.2m)
- Derivative financial asset of £0.6m as at 30 June 2023 (31 December 2022: £0.6m)
- Basic and diluted loss per share of 0.25p (30 June 2022: 0.58p)
- Successful fundraising – see separate announcement today

Portfolio

- In February 2023 an adaptive Phase 2/3 study for Lupuzor™ in SLE/Lupus patients was agreed with US partner, Avion Pharmaceuticals.
- In March 2023 a collaboration with Orano SA on ImmuPharma's peptide technology was announced.
- In May 2023, ImmuPharma received positive guidance from the Food and Drug Administration ("FDA") following the Pre-Investigational New Drug ("PIND") meeting supporting a Phase 2/3 adaptive clinical study of P140 in CIDP.
- In June 2023, confirmation that following receipt of comprehensive guidance from the FDA, a Phase 2/3 adaptive clinical trial of P140 (Lupuzor™) in patients with Lupus will commence in H2 2023.
- Established discussions with new potential corporate partners across the P140 platform and anti-infective programmes.

Corporate

- In August 2023, the Board was strengthened with two NED appointments: Dr Laurence Reilly & Dr Sébastien Goudreau.

Commenting on the statement and outlook Tim McCarthy, CEO and Chairman, said:

"We continue to make positive progressive steps for ImmuPharma. As a Board, we remain focused on bringing our two key late stage P140 clinical assets in Lupus and CIDP through their final clinical trials and to the market.

The drive to conclude further commercial and partnering deals will be accelerated over this next period and which is now bolstered by the recently announced new Board appointments.

The Board would like to take this opportunity to thank its shareholders for their continued patience and support, as well as its staff, corporate and scientific advisers and our partners including CNRS and Avion."

Market Abuse Regulation (MAR) Disclosure

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

For further information please contact:

ImmuPharma PLC (www.immupharma.co.uk) Tim McCarthy, Chief Executive Officer and Chairman Lisa Baderoon, Head of Investor Relations	+ 44 (0) 2072 062650 + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD) Neil Baldwin	+44 (0) 203 368 8974
Stanford Capital Partners (Joint Broker) Patrick Claridge, Bob Pountney	+44 (0) 203 815 8880
SI Capital (Joint Broker) Nick Emerson	+44 (0) 1483 413500

A copy of the interim report is available on the Company's website www.immupharma.co.uk